Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... Lilly and Gilead’s respective drugs.

Latest news

More from news
Approximately 174 fully matching, plus 383 partially matching documents found.

Latest Intelligence

  • Working together against COVID-19 Working together against COVID-19

    There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    The antiviral subcategory is a key focal point, with drugs such as Gilead Sciences’ remdesivir being tested in tens of trials and attracting the attention of the general public and world

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    One supporter of Gilead’s drug includes Bruce Aylward, a senior advisor at the World Health Organization (WHO). ... That initial data will likely come from the studies in China, which will be closely followed by an initial report from Gilead.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    For example, Gilead collaborated with Google’s Verily to study immunological disorders, and GlaxoSmithKline partnered with Google’s parent company Alphabet to found Galvani Bioelectronics.

More from intelligence
Approximately 4 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics